Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Flibanserin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Time Names Addyi Maker Sprout Pharma to 2026 Top 10
    Time Names Addyi Maker Sprout Pharma to 2026 Top 10

    29 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sprout-pharmaceuticals-makers-of-addyi-flibanserin-named-one-of-the-10-most-influential-health-and-life-science-companies-of-2026-by-time-302757517.html

    PR NEWSWIRE
    29 Apr 2026
    Share Share
    PHIL And Sprout Pharma Enhance Addyi Access Program
    PHIL And Sprout Pharma Enhance Addyi Access Program

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/phil-and-sprout-pharmaceuticals-expand-their-affordable-direct-to-patient-access-program-for-addyiflibanserin-302655793.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share
    FDA Approves Addyi For Postmenopausal Women's Sexual Health
    FDA Approves Addyi For Postmenopausal Women's Sexual Health

    15 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/historic-first-in-womens-sexual-health-fda-grants-approval-for-addyi-flibanserin-in-postmenopausal-women-302642397.html

    PR NEWSWIRE
    15 Dec 2025
    Share Share
    Addyi® Celebrates 10 Years Leading Women's Sexual Health
    Addyi® Celebrates 10 Years Leading Women's Sexual Health

    04 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/addyi-marks-a-decade-of-leadership-in-womens-sexual-health-302546088.html

    PR NEWSWIRE
    04 Sep 2025
    Share Share
    FDA Prioritizes Addyi® for Low Desire in Postmenopausal Women
    FDA Prioritizes Addyi® for Low Desire in Postmenopausal Women

    24 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-addyi-flibanserin-paving-the-way-for-expanded-access-to-treat-low-sexual-desire-in-postmenopausal-women-302512883.html

    PR NEWSWIRE
    24 Jul 2025
    Share Share
    FDA Warns Sprout Over Addyi Instagram Post, Lacking Ind
    FDA Warns Sprout Over Addyi Instagram Post, Lacking Ind

    11 Jun 2025

    // RAPS

    https://www.raps.org/news-and-articles/news-articles/2025/6/fda-warns-sprout-over-addyi-instagram-post,-clinic

    RAPS
    11 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.